// App-Quantinova.ai

164 : Long-term (four year) 28-joint count disease activity score (C-reactive protein) remission and improvements in skin disease with apremilast: phase III results from PALACE3

Researchers

Presenter

  • Christopher Edwards

Principal Investigators

  • Francisco J Blanco

  • Jeffrey Crowley

  • Maria Paris

  • Nikolay Delev

  • Lichen Teng

  • Charles A Birbara

Medical Centers

  • Rheumatology, University of Southampton NHS FT, Southampton, UNITED KINGDOM

  • Director of Research in the Biomedical Research Center, INIBIC-Hospital Universitario A Coruna, Galicia, SPAIN

  • Dermatology, Bakersfield Dermatology, Bakersfield, CA, USA

  • Drug Safety, Celgene Corporation, Summit, NJ, USA

  • Clinical R&D, Celgene Corporation, Summit, NJ, USA

  • Biostatistics, Celgene Corporation, Summit, NJ, USA

  • Medicine/Rheumatology, University of Massachusetts Medical School, Worcester, MA 01605, USA

Locations

  • United Kingdom

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved